IP Library › Granted Patent US 7,015,325
Granted Patent B2
US 7,015,325 · App. 10/149,288 · Granted Mar 21, 2006

Tryptase inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,015,325
App. No.
10/149,288
Granted
Mar 21, 2006
Kind
B2
Abstract

Compounds of the formula (I), in which M, A1, A2, K1 and K2 have the meanings indicated in the description are novel active tryptase inhibitors.

Claims (95)

1. A compound of the formula I

in which

M is a central building block of the formula below

n is 1 or 2,

U1 and U2 are identical or different and are methylene [—CH 2 —], ethylene [—CH 2 —CH 2 —], trimethylene [—CH 2 —CH 2 —CH 2 —], tetramethylene [—CH 2 —CH 2 —CH 2 —CH 2 —]or isopropylidene [—C(CH 3 ) 2 —],

A1 is A3-B1-A5-,

A2 is A4-B2-A6-,

A3 and A4 are identical or different and are —C(O)—, —O(C)—O—, —C(O)—NH—, —NH—C(O)—, —O—C(O)—NH—, —NH—C(O)—O—, —NH—C(O)—NH—, —O—C(O)—O—, —O—(CH 2 ) r —C(O)—, —O—(CH 2 ) m —O—C(O)— or —O—(CH 2 ) m —NH—C(O)—,

r is 1, 2, 3 or 4,

m is 1, 2, 3 or 4,

A5 and A6 are identical or different and are —C(O)—, —C(O)—NH—, —NH—C(O)—, —O—C(O)—NH—, —NH—C(O)—O—, —NH—C(O)—NH— or —O—C(O)—O—,

B1 and B2 are identical or different and are 1–4C-alkylene, 1–4-cyclohexylene, 1,3-cyclohexylene, 1,4-phenylene, 1,3-phenylene, 1,4-piperazinylene or 1,4-piperidinylene,

K1 is -B3-X1, -B3-Y1 or B3-Z1-B5-X1,

K2 is -B4-X2, -B4-Y2 or B4-Z2-B6-X2,

B3 and B4 are identical or different and are a bond or 1–4C-alkylene,

B5 and B6 are identical or different and are a bond or 1–2C-alkylene,

X1 and X2 are identical and are amino, aminocarbonyl or amidino,

Y1 and Y2 are imidazol-1-yl,

Z1 and Z2 are identical or different and are 5,2-pyridinylene, 6-methyl-5,2pyridinylene, 4,1-piperidinylene, 3,6-indazolylene, 3,6-indolylene, 1,3-phenylene, 1,4-phenylene, 1,3-cyclohexylene or 1,4-cyclohexylene,

and where on the direct route between the terminal nitrogen atoms 20 to 45 bonds have to be present, or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, or an N-oxide of the nitrogen-containing heteroaryls, heteroarylenes and heterocycloalkylenes, or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, where all those compounds are excluded in which, owing to the meaning of the variables A3, A4, A5, A6, B1, B2, B3, B4, Z1, Z2, X1 or X2, there would be a direct linkage of two heteroatoms.

2. A compound of the formula I according to claim 1 in which

M is a central building block of the formula below

n is 1 or 2,

U1 and U2 are identical or different and are methylene [—CH 2 —], ethylene [—CH 2 —CH 2 —], trimethylene [—CH 2 —CH 2 —CH 2 —], tetramethylene [—CH 2 —CH 2 —CH 2 —CH 2 —]or isopropylidene [—C(CH 3 ) 2 —],

A1 is -A3-B1-A5-,

A2 is -A4-B2-A6-,

A3 and A4 are identical or different and are —O—C(O)—, —NH—C(O)—, —O—C(O)—NH—, —NH—C(O)—O—, —NH—C(O)—NH—, —O—C(O)—O—, —O—(CH 2 ) r —C(O)—, —O—C(CH 2 ) m —O—C(O)— or —O—(CH 2 ) m —NH—C(O)—,

r is 1 or 2,

m is 2,

A5 and A6 are identical or different and are —C(O)—, —C(O)—NH—or —NH—C(O)—,

B1 and B2 are identical or different and are 1–4C-alkylene, 1,4-cyclohexylene, 1,3-cyclohexylene, 1,4-phenylene, 1,3-phenylene, 1,4-piperazinylene or 1,4-piperidinylene,

K1 is -B3-Z1-B5-X1,

K2 is -B4-Z2-B6-X2,

B3 and B4 are identical or different and are a bond or 1–2C-alkylene,

B5 and B6 are identical or different and are a bond or 1–2C-alkylene,

X1 and X2 are identical or different and are amino or amidino,

Z1 and Z2 are identical or different and are 1,3-phenylene, 1,4-phenylene, 1,3-cyclohexylene or 1,4-cyclohexylene,

and where on the direct route between the terminal nitrogen atoms 20 to 45 bonds have to be present, or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, where all those compounds are excluded in which, owing to the meaning of the variables A3, A4, A5, A6, B1 or B2, there would be a direct linkage of two heteroatoms.

3. A compound of the formula I according to claim 1 in which

M is a central building block of the formula below

n is 1 or 2,

U1 and U2 are identical or different and are methylene [—CH 2 —], tetramethylene [—CH 2 —CH 2 —CH 2 —CH 2 —] or isopropylidene [—C(CH 3 ) 2 —],

A1 is -A3-B1-A5-,

A2 is -A4-B2-A6-,

A3 and A4 are identical or different and are —O—C(O)—, —O—C(O)—NH— or —O—(CH 2 ) m —O—C(O)—,

m is 2,

A5 and A6 are identical or different and are —C(O)—, —C(O)—NH— or —NH—C(O)—,

B1 and B2 are identical or different and are ethylene or 1,4-piperazinylene,

K1 is -B3-Z1-B5-X1,

K2 is -B4-Z2-B6-X2,

B3 and B4 are identical or different and are a bond or methylene,

B5 and B6 are identical and are methylene,

X1 and X2 are identical and are amino,

Z1 and Z2 are identical or different and are 1,3-phenylene, 1,4-phenylene or 1,4-cyclohexylene,

and where on the direct route between the terminal nitrogen atoms 20 to 45 bonds have to be present, or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, where all those compounds are excluded in which, owing to the meaning of the variables A3, A4, A5, A6, B1 or B2, there would be a direct linkage of two heteroatoms.

4. A compound of the formula I according to claim 1 in which

M is a central building block of the formula below

n is 1 or 2,

U1 and U2 are identical or different and are methylene [—CH 2 —] or isopropylidene [—C(CH 3 ) 2 —],

A1 is -A3-B1-A5-,

A2 is -A4-B2-A6-,

A3 and A4 are identical or different and are —O—C(O)—, —O—C(O)—NH—or —O—(CH 2 ) m —O—C(O)—,

m is 2,

A5 and A6 are identical or different and are —C(O)—, —C(O)—NH—or —NH—C(O)—,

B1 and B2 are identical or different and are ethylene or 1,4-piperazinylene,

K1 is -B3-Z1-B5-X1,

K2 is -B4-Z2-B6-X2,

B3 and B4 are identical and are a bond or methylene,

B5 and B6 are identical and are methylene,

X1 and X2 are identical and are amino,

Z1 and Z2 are identical or different and are 1,3-phenylene, 1,4-phenylene or 1,4-cyclohexylene,

and where on the direct route between the terminal nitrogen atoms 20 to 45 bonds have to be present, or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, where all those compounds are excluded in which, owing to the meaning of the variables A3, A4, A5, A6, B1 or B2, there would be a direct linkage of two heteroatoms.

5. A compound of the formula I according to claim 1 in which M is a central building block of the formula below

n is 1 or 2,

U1 and U2 are identical and are methylene [—CH 2 —] or tetramethylene [—CH 2 —CH 2 —CH 2 —CH 2 —],

A1 is -A3-B1-A5-,

A2 is -A4-B2-A6-,

A3 and A4 are identical and are —O—C(O)— or —O—(CH 2 ) m —O—C(O)—,

m is 2,

A5 and A6 are identical and are —C(O)— or —C(O)—NH—,

B1 and B2 are identical and are 1,4-piperazinylene,

K1 is -B3-Z1-B5-X1,

K2 is -B4-Z2-B6-X2,

B3 and B4 are identical and are a bond or methylene,

B5 and B6 are identical and are methylene,

X1 and X2 are identical and are amino,

Z1 and Z2 are identical and are 1,3-phenylene, 1,4-phenylene or 1,4-cyclohexylene,

and where on the direct route between the terminal nitrogen atoms 20 to 45 bonds have to be present, or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

6. A compound of the formula I according to claim 1 with the chemical designation 1,4-bis-[4-(trans-4-aminomethylcyclohexylcarbonyl)-1-piperazinylcarbonyl-1-oxyethyl-2-oxy]-2-butyne, 1,4-bis-[4-(4-aminomethylbenzylaminocarbonyl)-1-piperazinylcarbonyl-1-oxyethyl-2-oxy]-2-butyne, 1,4-bis-[4-(3-aminomethylbenzylaminocarbonyl)-1-piperazinylcarbonyl-1-oxyethyl-2-oxy]-2-butyne, 1,6-bis-[4-(4-aminomethylbenzylaminocarboflyl)-1-piperazinylcarbonyl-1-oxy]-2,4-hexadiyne, 1,12-bis-[4-(4-aminomethylbenzylaminocarbonyl)-1-piperazinylcarbonyl-1-oxy]-5,7-dodecadiyne, 1,12-bis-[4-(3-aminomethylbenzylaminocarbonyl)-1-piperazinylcarbonyl-1-oxy]-5,7-dodecadiyne, 1,6-bis-[4-(3-aminomethylbenzylaminocarbonyl)-1-piperazinylcarbonyl-1-oxy]-2,4-hexadlyne, or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

7. A method of treating or preventing a disease or disorder in a patient comprising administering to a patient in need thereof a therapeutically effective amount of one or more compounds of the formula I according to claim 1 or a pharmaceutically acceptable hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, or an N-oxide of the nitrogen-containing heteroaryls, heteroarylenes and heterocycloalkylenes, or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof,

wherein said disease or disorder is selected from the group consisting of bronchitis, allergic bronchitis, bronchial asthma, COPD, allergic conjunctivitis, allergic rhinitis, rheumatoid arthritis, dermatitis, psoriasis, Crohn's disease and inflammatory bowel disease.

8. A pharmaceutical composition comprising one or more compounds of the formula I according to claim 1 or a pharmaceutically acceptable hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, or an N-oxide of the nitrogen-containing heteroaryls, heteroarylenes and heterocycloalkylenes, or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof,

together with a pharmaceutical auxiliary and/or excipient.

9. A method of treating or preventing an airway disorder in a patient comprising administering to a patient in need thereof a therapeutically effective amount of one or more compounds of the formula I according to claim 1 or a pharmaceutically acceptable hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, or an N-oxide of the nitrogen-containing heteroaryls, heteroarylenes and heterocycloalkylenes, or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

10. The method according to claim 9 , wherein the airway disorder is selected from the group consisting of bronchitis, allergic bronchitis, bronchial asthma, COPD and allergic rhinitis.